THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE Patent applications |
Patent application number | Title | Published |
20140155420 | INHIBITORS OF EYA2 - The invention provides small molecule inhibitors of EYA2 phosphatase activity and EYA2 binding to Six1. These inhibitors are proposed for use in methods of treating cancer in a subject, such as those involving Six1 and/or EYA2 disregulation. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject. | 06-05-2014 |
20140154283 | IDENTIFICATION OF A WEST NILE VIRUS CD4 T CELL EPITOPE AND USE THEREOF - Described herein is the identification and of a potent West Nile virus (WNV) CD4 positive T cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (DENV-2) DNA and virus-like particle (VLP) vaccines. Also described are methods for the identification of potent T cell epitopes to enhance immunogenicity of multivalent vaccines. | 06-05-2014 |
20130224207 | IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE - Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses. | 08-29-2013 |
20130210010 | RAPID SALMONELLA SEROTYPING ASSAY - Processes for the serotype specific detection and identification of one or more | 08-15-2013 |
20130189264 | A NOVEL CHIMERIC PROTEIN FOR PREVENTION AND TREATMENT OF HIV INFECTION - This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker. | 07-25-2013 |
20130018089 | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 01-17-2013 |
20120258144 | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 10-11-2012 |
20120190041 | METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis. | 07-26-2012 |
20120184049 | METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis. | 07-19-2012 |
20120160010 | AIR-SAMPLING DEVICE AND METHOD OF USE - The present disclosure concerns embodiments of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. In one representative embodiment, the sampling apparatus includes a collection-vessel retaining member that is adapted to be removably coupled to a collection vessel. The retaining member has an air-inlet conduit for permitting air to flow through the open end of the collection vessel and an air-outlet conduit for permitting air to exit the open end of the collection vessel. The air-inlet conduit and the air-outlet conduit are configured to cause air flowing into the collection vessel to establishes a cyclonic flow path, which causes airborne particles to separate out from the air stream and collect in the collection vessel. | 06-28-2012 |
20120129161 | METHODS FOR MODULATING EMBRYONIC STEM CELL DIFFERENTIATION - Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described. Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters. | 05-24-2012 |
20120027753 | MicroRNAs in Never-Smokers and Related Materials and Methods - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer in never-smokers. The invention also provides methods of identifying anti-lung cancer agents. | 02-02-2012 |
20110315477 | ELECTROADHESION DEVICE FOR IMPROVING EXTENSION LADDER STABILITY - A method of stabilizing a ladder is provided by attaching one or more electroadhesive devices to an attachment point on the ladder and contacting the device to a surface such as a wall or the floor. The electrostatic force achieved by applying a voltage difference in the device provides decreased ladder slip angles or increased shear forces required to create ladder slippage thereby improving ladder stability. | 12-29-2011 |
20110301094 | NEW TUMOR SUPPRESSOR GENE, P28ING5 - This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided. | 12-08-2011 |
20110217312 | TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS - Immunogenic compositions and methods for eliciting an immune response against | 09-08-2011 |
20110142831 | USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 06-16-2011 |
20110053843 | E-SELECTIN COMPOSITIONS AND USE THEREOF FOR INDUCING E-SELECTIN TOLERANCE - The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia. | 03-03-2011 |
20110053264 | FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein. | 03-03-2011 |
20100317034 | PRIMATE T-LYMPHOTROPIC VIRUSES - Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses. | 12-16-2010 |
20100120898 | MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma - Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents. | 05-13-2010 |
20100098703 | DETERMINATION OF AM-BINDING PROTEINS AND THE ASSOCIATION OF ADRENOMEDULLIN (AM) THEREWITH - The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies. The present invention additionally provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents. | 04-22-2010 |
20100003273 | NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION - The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection. | 01-07-2010 |
20090239220 | DLC-1 GENE DELETED IN CANCERS - A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented. | 09-24-2009 |
20090203716 | Pyrimidine low molecular weight ligands for modulating hormone receptors - Disclosed herein are small molecule modulators hormone receptors, including agonists and antagonists of luteinizing hormone/choriogonadotropin, follicle stimulating hormone and thyroid stimulating hormone receptors. Exemplary disclosed compounds include those of the formula | 08-13-2009 |
20090202552 | GENE EXPRESSED IN PROSTATE CANCER AND METHODS OF USE - A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer. | 08-13-2009 |
20090175823 | METHOD OF TREATING AUTOIMMUNE DISEASES WITH INTERFERON-BETA AND IL-2R ANTAGONIST - Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease. | 07-09-2009 |
20090142310 | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 06-04-2009 |
20090111107 | TUMOR SUPPRESSOR GENE P33ING2 - The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins. | 04-30-2009 |
20090111089 | PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES - Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed. | 04-30-2009 |
20090099122 | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE EPITHELIAL CELL GROWTH - This disclosure provides a method of inducing epithelial cell growth. The method includes administering an effective amount of a K-type CpG oligonucleotide, thereby inducing epithelial cell growth. The epithelial cell can be in vivo or in vitro. Methods are also provided for inducing wound healing in a subject. The methods include administering to the subject a therapeutically effective amount of at least on K-type CpG ODN. | 04-16-2009 |
20090087852 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 04-02-2009 |
20090068733 | T2R, a novel family of taste receptors - The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors. | 03-12-2009 |
20090061447 | HIGH SPEED PARALLEL MOLECULAR NUCLEIC ACID SEQUENCING - A method and device is disclosed for high speed, automated sequencing of nucleic acid molecules. A nucleic acid molecule to be sequenced is exposed to a polymerase in the presence of nucleotides which are to be incorporated into a complementary nucleic acid strand. The polymerase carries a donor fluorophore, and each type of nucleotide (e.g. A, T/U, C and G) carries a distinguishable acceptor fluorophore characteristic of the particular type of nucleotide. As the polymerase incorporates individual nucleic acid molecules into a complementary strand, a laser continuously irradiates the donor fluorophore, at a wavelength that causes it to emit an emission signal (but the laser wavelength does not stimulate the acceptor fluorophore). In particular embodiments, no laser is needed if the donor fluorophore is a luminescent molecule or is stimulated by one. The emission signal from the polymerase is capable of stimulating any of the donor fluorophores (but not acceptor fluorophores), so that as a nucleotide is added by the polymerase, the acceptor fluorophore emits a signal associated with the type of nucleotide added to the complementary strand. The series of emission signals from the acceptor fluorophores is detected, and correlated with a sequence of nucleotides that correspond to the sequence of emission signals. | 03-05-2009 |
20090053255 | Anti-arthropod vector vaccines, methods of selecting and uses thereof - The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis. | 02-26-2009 |
20090048170 | TARGET FOR ANTI-ANGIOGENESIS THERAPY - The present disclosure concerns the use of peptides and compositions, such as pharmaceutical compositions, to influence angiogenesis. Particular methods are useful for promoting angiogenesis, while others are particularly useful for inhibiting angiogenesis. | 02-19-2009 |
20090029908 | UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS - Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments. | 01-29-2009 |
20090010517 | NON-INVASIVE IN VIVO MRI AXON DIAMETER MEASUREMENT METHODS - Magnetic resonance methods include modeling magnetic resonance signals obtained from specimens at low and high q-values to obtain parameters and distributions of parameters associated with specimen structure and orientation. In evaluation of brain white matter specimens, diffusion within axons can be modeled based on hindered diffusion parallel to an axis of the axon and restricted diffusion perpendicular to the axis. Diffusion exterior to axons can be modeled as hindered diffusion with differing diffusivities parallel to and perpendicular to the axis. Based on extracted parameters and associated model functions, distributions of specimen properties such as intra and extra-axonal principal diffusivities and the corresponding principal directions can be estimated. Features of the axon diameter distribution can also be estimated using this approach. | 01-08-2009 |
20080248994 | Methods of using deacetylase inhibitors to promote cell differentiation and regeneration - A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition. | 10-09-2008 |
20080227093 | PHENYLTHIOCARBAMIDE (PTC) TASTE RECEPTOR - The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor. | 09-18-2008 |